Clinical Trials
2 trialsNCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT04359784 2025-10-23
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Completed